Switch theme
Sign up to access all valuation multiples
Emami Ltd is a fast-moving consumer goods company engaged in manufacturing and marketing of personal care & healthcare products.. The company's portfolio includes trusted power brands like Navratna, BoroPlus, Fair & Handsome, Zandu Balm, Mentho Plus and Kesh King.
1983
3.3K+
LTM Revenue $444M
LTM EBITDA $122M
$3.0B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Emami has a last 12-month revenue of $444M and a last 12-month EBITDA of $122M.
In the most recent fiscal year, Emami achieved revenue of $410M and an EBITDA of $115M.
Emami expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Emami valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $390M | $410M | XXX | XXX | XXX |
| Gross Profit | $239M | $251M | XXX | XXX | XXX |
| Gross Margin | 61% | 61% | XXX | XXX | XXX |
| EBITDA | $107M | $115M | XXX | XXX | XXX |
| EBITDA Margin | 27% | 28% | XXX | XXX | XXX |
| Net Profit | $97.4M | $74.3M | XXX | XXX | XXX |
| Net Margin | 25% | 18% | XXX | XXX | XXX |
| Net Debt | $27.4M | $3.1M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Emami's stock price is INR 608 (or $7).
Emami has current market cap of INR 265B (or $3.1B), and EV of INR 259B (or $3.0B).
See Emami trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $3.0B | $3.1B | XXX | XXX | XXX | XXX | $0.23 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Emami has market cap of $3.1B and EV of $3.0B.
Emami's trades at 6.8x LTM EV/Revenue multiple, and 24.6x LTM EBITDA.
Analysts estimate Emami's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Emami and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $3.0B | XXX | XXX | XXX |
| EV/Revenue | 6.9x | XXX | XXX | XXX |
| EV/EBITDA | 25.1x | XXX | XXX | XXX |
| P/E | 32.4x | XXX | XXX | XXX |
| P/E/Growth | 3.3x | XXX | XXX | XXX |
| EV/FCF | 31.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEmami's NTM/LTM revenue growth is 8%
Emami's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Emami's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Emami's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Emami and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 28% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 7% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 36% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 21% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 45% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Acme United | XXX | XXX | XXX | XXX | XXX | XXX |
| EZZ Life Science | XXX | XXX | XXX | XXX | XXX | XXX |
| Live Verdure | XXX | XXX | XXX | XXX | XXX | XXX |
| Lavipharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Sarantis Group | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Emami acquired XXX companies to date.
Last acquisition by Emami was XXXXXXXX, XXXXX XXXXX XXXXXX . Emami acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Emami founded? | Emami was founded in 1983. |
| Where is Emami headquartered? | Emami is headquartered in India. |
| How many employees does Emami have? | As of today, Emami has 3.3K+ employees. |
| Is Emami publicy listed? | Yes, Emami is a public company listed on BOM. |
| What is the stock symbol of Emami? | Emami trades under 531162 ticker. |
| When did Emami go public? | Emami went public in 2000. |
| Who are competitors of Emami? | Similar companies to Emami include e.g. Acme United, EZZ Life Science, Live Verdure, Lavipharm. |
| What is the current market cap of Emami? | Emami's current market cap is $3.1B |
| What is the current revenue of Emami? | Emami's last 12-month revenue is $444M. |
| What is the current EBITDA of Emami? | Emami's last 12-month EBITDA is $122M. |
| What is the current EV/Revenue multiple of Emami? | Current revenue multiple of Emami is 6.8x. |
| What is the current EV/EBITDA multiple of Emami? | Current EBITDA multiple of Emami is 24.6x. |
| What is the current revenue growth of Emami? | Emami revenue growth between 2023 and 2024 was 5%. |
| Is Emami profitable? | Yes, Emami is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
